Morningstar‘s Stock Analysis STMM
Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Company Profile STMM
Stemcell Holdings Inc, through its subsidiary, is engaged in the regenerative medicine-related business which includes but is not limited to providing technical assistance to the culturing, storing and delivery of stem cells and administrative and consulting services to clinics. The company provides two different options for stem cell regenerative therapy: autologous adipose derived mesenchymal stem cells and natural killer cells.
Tokyo, 107-0061, Japan